Journals / Medicine Science / 2016 / Cilt: 5 - Sayı: 1

Clinical Significance of Neutrophil to Lymphocyte Ratio and Mean Platelet Volume for Predicting the Severity of Hepatic Fibrosis in Patients with Chronic Hepatitis B

Kronik Hepatit B Hastalarında Karaciğer Fibrozisinin Ciddiyetinin Belirlenmesinde Nötrofil/Lenfosit Oranı ve Ortalama Trombosit Hacminin Klinik Önemi

Pages
147–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are required to determine the associations between NLR, MPV and the severity of fibrosis in chronic hepatitis B patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we aimed to determine the clinical significance of the neutrophil to lymphocyte (NLR) ratio, mean platelet volume (MPV) and other biochemical parameters for predicting the degree of liver fibrosis in patients with chronic hepatitis B (CHB) infection.
📊
Key Findings & Data:A total of 95 biopsy-proven naïve CHB cases patients were included in the study.
💡
Conclusion & Impact:Further studies are required to determine the associations between NLR, MPV and the severity of fibrosis in chronic hepatitis B patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study, we aimed to determine the clinical significance of the neutrophil to lymphocyte (NLR) ratio, mean platelet volume (MPV) and other biochemical parameters for predicting the degree of liver fibrosis in patients with chronic hepatitis B (CHB) infection. A total of 95 biopsy-proven naïve CHB cases patients were included in the study. The complete blood count variables including white blood cell, hemoglobin, hematocrit, platelet count, neutrophil, lymphocyte, MPV, and other routine biochemical parameters were tested. Liver biopsy samples were examined using the Ishak scoring system. Individuals with a fibrosis score of 0, 1 and 2 were included in Group 1 and 3,4,5 and 6 were included in Group 2. Data analyses were carried out using SPSS 15 software. Statistical significance was set at a p-value of less than 0.05.Of the 95 cases, 76 (80%) were men and 19 (20%) were women. The mean age of the patients was 39.91±18.6 years, and 30 cases (31.5%) had HBeAg positivity. Fibrosis scores of 36 cases (37.8%) were greater than or equal to 3, whereas 59 cases (62.2%) had fibrosis scores less than 3. There was a significant difference between these two groups for NLR (Group 1; 2.38± 0.96, Group 2; 1.64 ± 0.60, p<0.001) and MPV (Group 1; 8.13± 1.20, Group 2; 8.77 ± 1.47, p<0.05). We have compared the receiver operating characteristic curves for the diagnostic performance of aspartate aminotransferase, alanine aminotransferase, platelet count, NLR, MPV, and albumin identifying fibrosis in CHB and area under the curve values for these variables were 0.70, 0.49, 0.27, 0.20, 0.67, and 0.13, respectively.NLR values were significantly lower and MPV values were significantly higher in hepatitis B virus-infected patients with advanced liver fibrosis and can be defined as independent noninvasive predicting factors for hepatic fibrosis. Further studies are required to determine the associations between NLR, MPV and the severity of fibrosis in chronic hepatitis B patients

Özet

Bu çalışmada; kronik hepatit B hastalarında nötrofil/lenfosit oranı (NLO), ortalama trombosit hacmi (OTH) ve diğer biyokimyasal parametrelerin karaciğer fibrozisinin ciddiyetini belirlemedeki klinik önemini değerlendirmeyi amaçladık. Karaciğer biyopsisi uygulanmış toplam 95 naif KHB hastası çalışmaya dahil edildi. Lökosit, trombosit, hemoglobin sayımı, nötrofil, lenfosit, OTH ve diğer rutin biyokimyasal parametreler test edildi. Ishak skorlama sistemine göre karaciğer biyopsi örnekleri incelendi. Fibrozis derecesi 0, 1 ve 2 olanlar Grup 1, fibrozis düzeyi 3 ve üzeri olanlar Grup 2 olarak belirlendi. Mevcut verilerimizin analizleri SPSS 15 programı ile gerçekleştirildi. 'p' değerinin <0,05 olduğu sonuçlar istatistiksel olarak anlamlı kabul edildi. 95 hastadan, 76'sı erkek (%80) ve 19'u kadındı (%20). Hastaların ortalama yaşı 39.91±18.6 yıldı, 30 vakanın (%31,5) HBeAg pozitifliği mevcuttu. 36 hastanın (%37,8) fibrozis skoru 3 ve üzerinde idi, buna karşılık 59 hastanın (%62,2) fibrozis skoru 3'ün altındaydı. İki grup arasında NLO (Group 1: 2,38± 0,96, Group 2: 1,64 ± 0,60, p<0,001) ve OTH (Group 1: 8,13± 1,20, Group 2: 8,77 ± 1,47, p<0,05) açısından anlamlı farklılık mevcuttu. KHB hastalarında, fibrozis ciddiyetini ortaya koyabilecek tanısal performanslarını belirlemek amaçlı AST, ALT, trombosit, NLO, OTH ve albümin için ROC (Receiver Operating Characteristic) eğrileri çizildi ve kıyaslamalar yapıldı, eğri altında kalan alanlar sırasıyla 0,70, 0,49, 0,27, 0,20, 0,67 ve 0,13'tü. İleri düzeyde karaciğer fibrozisi olan KHB hastalarında, NLO düzeyleri anlamlı düzeyde düşük ve OTH düzeyleri anlamlı düzeyde yüksek olduğundan bu iki parametre hepatik fibrozisi belirleme açısından bağımsız noninvazif belirteçler olarak tanımlanabilirler. Kronik hepatit B hastalarında, fibrozis ciddiyeti ile NLO ve OTH arasındaki ilişkiyi irdeleyecek ileri çalışmalara ihtiyaç duyulmaktadır

🔖

Cite This Article

TANOĞLU, A., KARAGÖZ, E., ÜLÇAY, A., TURHAN, V., KARA, M., YAZGAN, Y. (2016). Clinical Significance of Neutrophil to Lymphocyte Ratio and Mean Platelet Volume for Predicting the Severity of Hepatic Fibrosis in Patients with Chronic Hepatitis B. Medicine Science, Cilt: 5 - Sayı: 1, 147–159. https://ajindex.com/articles/277522

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81
  2. Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol. 2015;7(11):1541-52
  3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52
  4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263-83
  5. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex: a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45(2):297-306
  6. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the fibrotest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49(3):450-4
  7. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51(10):1867-73
  8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26
  9. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47-58
  10. Beyan C. Is mean platelet volume a predictive marker in patients with venous thrombosis? Clin Appl Thromb Hemost. 2012;18(6):670-1
  11. Hendra TJ, Oswald GA, Yudkin JS. Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. Diabetes Research and Clinical Practice. 1988;5(1):63-9
  12. Lancé MD, Sloep M, Henskens YM, Marcus MA. Mean platelet volume as a diagnostic marker for cardiovascular disease: drawbacks of preanalytical conditions and measuring techniques. Clin Appl Thromb Hemost. 2012;18(6):561-8
  13. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a li